Pfizer (PFE) Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Pfizer Inc. (NYSE: PFE) | Delayed: 29.84 -0.58 (1.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.42 | 52 Week High | $37.39 | |||
| Open | $30.28 | 52 Week Low | $28.25 | |||
| Day High | $30.32 | P/E | 18.08 | |||
| Day Low | $29.83 | EPS | $1.65 | |||
| Volume | 3,347,135 | |||||
